Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
41
datasets available to search
ShareScore release 0.9.0
Dataset results
41 results for “HIV and AIDS”
Data from: Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): a randomized trial and cost-effectiveness analysis
<p>Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD). Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD).</p> <p>In this open, three-arm randomised trial, adults (≥18 years) with cough attending acute primary services in Malawi were randomised (1:1:1) to standard-of-care (SOC); oral HIV testing (HIV screening) and linkage to care; or HIV testing and linkage to care plus DCXR-CAD with sputum Xpert for high CAD4TBv5 scores (HIV-TB screening). Participants and study staff were not blinded to intervention allocation, but investigator blinding was maintained until final analysis. The primary outcome was time to TB treatment. Secondary outcomes included proportion with same-day TB treatment; prevalence of undiagnosed/untreated bacteriologically-confirmed TB on day 56; and undiagnosed/untreated HIV. Analysis was done on an intention to treat basis. Cost-effectiveness analysis used a health-provider perspective. Between 15/11/2018-27/11/2019, 8236 were screened for eligibility, with 473, 492, and 497 randomly allocated to SOC, HIV, and HIV-TB screening arms; 53 (11%), 52 (9%), and 47 (9%) were lost to follow-up, respectively. At 56 days, TB treatment had been started in 5 (1.1%) SOC, 8 (1.6%) HIV-screening, and 15 (3.0%) HIV-TB screening participants. Median (IQR) time to TB treatment was 11 (6.5-38), 6 (1-22) and 1 (0-3) days (hazard ratio for HIV-TB vs. SOC: 2.86, 1.04-7.87), with same-day treatment of 0/5 (0%) SOC, 1/8 (12.5%) HIV, and 6/15 (40.0%) HIV-TB screening arm TB patients (p=0.03). At day 56, 2 SOC (0.5%), 4 HIV (1.0%), and 2 HIV-TB (0.5%) participants had undiagnosed microbiologically-confirmed TB. HIV screening reduced the proportion with undiagnosed or untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in the HIV-screening arm (risk ratio [RR]: 0.18, 0.04-0.83), and 1 (0.2%) in the HIV-TB screening arm (RR: 0.09, 0.01-0.71). Incremental costs were US$3.58 and US$19.92 per participant screened for HIV and HIV-TB; the probability of cost-effectiveness at a US$1200/quality-adjusted life-year (QALY) threshold were 83.9% and 0%. Main limitations were the lower than anticipated prevalence of tuberculosis and short participant follow-up period; cost and quality of life benefits of this screening approach may accrue over a longer time horizon.</p> <p>DCXR-CAD with universal HIV screening significantly increased the timeliness and completeness of HIV and TB diagnosis. If implemented at scale this has potential to rapidly and efficiently improve TB and HIV diagnosis and treatment.</p>
APLICATIVO MÓVEL PARA EDUCAÇÃO E PREVENÇÃO DE HIV E AIDS: DESENVOLVIMENTO E AVALIAÇÃO
<p>O HIV e a AIDS são doenças sexualmente transmissíveis que continuam a ser uma importante preocupação de saúde pública. A educação e a prevenção são fundamentais para reduzir a transmissão dessas doenças. Este estudo teve como objetivo desenvolver e avaliar um aplicativo móvel para educação e prevenção de HIV e AIDS. O aplicativo será desenvolvido por um Analista de Sistemas, orientado pelos autores do TCC, de modo que todos os requisitos serão pesquisados, avaliados e entregues ao desenvolvedor para a construção do mesmo, requisitos esses que foram baseados em evidências científicas. O desenvolvimento do aplicativo seguirá as melhores práticas de design de interface do usuário (UI/UX) e será baseado em informações precisas e atualizadas sobre o HIV/AIDS, obtidas de fontes confiáveis. Os levantamentos que foram feitos para os requisitos levaram em conta Softwares existentes e a pesquisa sobre informações atualizadas sobre HI/AIDS servirão de base para o desenvolvimento do aplicativo. O aplicativo incluiu as seguintes informações: Epidemiologia do HIV e da AIDS; Transmissão do HIV e da AIDS; Prevenção do HIV e da AIDS; Tratamento do HIV e da AIDS; Locais adequados para realização de exames; Os resultados deste estudo sugerem que o aplicativo móvel é uma ferramenta promissora para educação e prevenção de HIV e AIDS. O aplicativo é acessível, fácil de usar e fornece informações precisas e atualizadas e espera-se que a avaliação após a implantação revele um aumento significativo no conhecimento sobre o HIV/AIDS entre os usuários do aplicativo, bem como uma maior conscientização sobre a importância da prevenção.</p>
AIDS 347: IL-6 Blockade in Treated HIV Infection
ClinicalTrials.gov study NCT02049437. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
ClinicalTrials.gov study NCT00887679. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms
ClinicalTrials.gov study NCT03182738. IPD Sharing: NO. Countries: 1. Publications: 2.
Data from: Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): a randomized trial and cost-effectiveness analysis
Open the record for dataset details and reuse information.
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
ClinicalTrials.gov study NCT03141918. IPD Sharing: NO. Countries: 1. Publications: 3.
A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infectio
ClinicalTrials.gov study NCT00000702. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
ClinicalTrials.gov study NCT00000735. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC
ClinicalTrials.gov study NCT00000999. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials G
ClinicalTrials.gov study NCT00000815. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
ClinicalTrials.gov study NCT00000646. IPD Sharing: Not stated. Countries: 1. Publications: 3.
IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV Patients
ClinicalTrials.gov study NCT04735445. IPD Sharing: Not stated. Countries: 1. Publications: 19.
A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP
ClinicalTrials.gov study NCT00000700. IPD Sharing: Not stated. Countries: 1. Publications: 7.
AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers
ClinicalTrials.gov study NCT00121758. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
ClinicalTrials.gov study NCT00000867. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cancer Prevalence and Outcomes in Individuals With HIV and AIDS: Multicenter BUHASDER Study
ClinicalTrials.gov study NCT06774495. IPD Sharing: YES. Countries: 1. Publications: 4.
A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications
ClinicalTrials.gov study NCT00001078. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
ClinicalTrials.gov study NCT00000994. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
ClinicalTrials.gov study NCT00002414. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.